NYSE: TMOThermo Fisher Scientific Inc Stock
$465.15+0.24 (0.05%)
Updated Jun 11, 2021
TMO Price
$465.15
Fair Value Price
N/A
Market Cap
$182.82B
52 Week Low
$341.46
52 Week High
$532.57
P/E
23.22x
P/B
5.21x
P/S
5.01x
PEG
14.83x
Dividend Yield
0.15%
Revenue
$35.89B
Earnings
$7.92B
Gross Margin
51.5%
Operating Margin
27.03%
Profit Margin
22.1%
Debt to Equity
0.88
Operating Cash Flow
$10B
Beta
0.86
Next Earnings
Jul 20, 2021
Ex-Dividend
Jun 14, 2021
Next Dividend
Jul 15, 2021
Zen Score
High
Medium
Low
60
Industry average
Reasons for this score
TMO ($465.15) is trading below its intrinsic value of $510.08, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
TMO is good value based on its earnings relative to its share price (23.22x), compared to the US market average 27.98x)
Valuation
TMO is good value based on its earnings relative to its share price (23.22x), compared to the US Diagnostics & Research industry average (33.47x)
Valuation
TMO News
Valuation
TMO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
23.22x
Industry
33.47x
Market
27.98x
TMO is good value based on its earnings relative to its share price (23.22x), compared to the US market average 27.98x)
Valuation
TMO is good value based on its earnings relative to its share price (23.22x), compared to the US Diagnostics & Research industry average (33.47x)
Valuation
TMO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.21x
Industry
5.9x
TMO is good value based on its book value relative to its share price (5.21x), compared to the US Diagnostics & Research industry average (5.9x)
Valuation
TMO price to earnings growth (PEG)
For valuing profitable companies with growth potential
TMO is poor value relative to its rate of earnings growth, measured by PEG ratio (14.83x)
Valuation
TMO's financial health
Profit margin
Revenue
$9.9B
Net Income
$2.3B
Profit Margin
23.6%
TMO's Earnings (EBIT) of $9.70B can safely cover interest payments on company debt ($18.65B)
Financials
TMO's profit margin has increased (+7.8%) in the last year from (14.3%) to (22.1%)
Financials
Assets to liabilities
Assets
$65.9B
Liabilities
$30.9B
Debt to equity
0.53
TMO's short-term assets ($17.69B) exceed its short-term liabilities ($7.00B)
Financials
TMO's long-term liabilities ($23.88B) exceed its short-term assets ($17.69B)
Financials
TMO's debt relative to shareholder equity (0.88) has decreased or remained constant compared to 5 years ago (1.05)
Financials
TMO's debt to equity ratio (0.88) is considered high
Financials
Cash flow
Operating
$2.0B
Investing
-$2.0B
Financing
-$4.9B
TMO's operating cash flow ($9.91B) is sufficient to service the company's debt ($18.65B)
Financials
Thermo Fisher Scientific Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.